524414 NORRIS

Norris Medicines Share Price

 

 

Start SIP in NORRIS

Start SIP

Performance

  • Low
  • ₹14
  • High
  • ₹16
  • 52 Week Low
  • ₹13
  • 52 Week High
  • ₹22
  • Open Price₹16
  • Previous Close₹15
  • Volume1,489
  • 50 DMA₹14.90
  • 100 DMA₹15.53
  • 200 DMA₹16.27

Investment Returns

  • Over 1 Month -5%
  • Over 3 Month -13.64%
  • Over 6 Month -19.13%
  • Over 1 Year -35.81%

Smart Investing Starts Here Start SIP with Norris Medicines for Steady Growth!

Invest Now

Norris Medicines Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -9.3
  • PEG Ratio
  • 0.1
  • Market Cap Cr
  • 14
  • P/B Ratio
  • -0.9
  • Average True Range
  • 1.11
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.47
  • RSI
  • 48.48
  • MFI
  • 74.05

Norris Medicines Financials

Norris Medicines Technicals

EMA & SMA

Current Price
₹14.25
-0.5 (-3.39%)
pointer
  • Bearish Moving Average 11
  • Bullish Moving Average 5
  • 20 Day
  • ₹14.28
  • 50 Day
  • ₹14.90
  • 100 Day
  • ₹15.53
  • 200 Day
  • ₹16.27

Resistance and Support

14.43 Pivot Speed
  • R3 17.27
  • R2 16.38
  • R1 15.32
  • S1 13.37
  • S2 12.48
  • S3 11.42

Ratings

Master Rating

EPS Strenth

N/A

Price Strength

Buyer Demand

Group Rank

Norris Medicines has an operating revenue of Rs. 7.28 Cr. on a trailing 12-month basis. An annual revenue growth of 4% is not great, Pre-tax margin of -20% needs improvement, NULL From an O'Neil Methodology perspective, the stock has an EPS Rank of 0 which is a POOR score indicating inconsistency in earnings, a RS Rating of 35 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 89 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Norris Medicines Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-14 Quarterly Results
2025-08-14 Quarterly Results
2025-05-28 Audited Results
2025-02-13 Quarterly Results & Others Inter-alia, to consider 1. Requests from Mr. Nimish Bhishma Thakore, for reclassification from Promoter / Promoter Group into Public Category. 2. Other business matters.
2024-11-14 Quarterly Results

Norris Medicines F&O

Norris Medicines Shareholding Pattern

34%
0.01%
0.06%
20.79%
45.14%

Norris Medicines FAQs

Norris Medicines share price is ₹14 As on 10 February, 2026 | 07:32

The Market Cap of Norris Medicines is ₹14.3 Cr As on 10 February, 2026 | 07:32

The P/E ratio of Norris Medicines is -9.3 As on 10 February, 2026 | 07:32

The PB ratio of Norris Medicines is -0.9 As on 10 February, 2026 | 07:32

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23